Literature DB >> 10757795

The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.

P H Giangrande1, E A Kimbrel, D P Edwards, D P McDonnell.   

Abstract

The human progesterone receptor (PR) exists as two functionally distinct isoforms, hPRA and hPRB. hPRB functions as a transcriptional activator in most cell and promoter contexts, while hPRA is transcriptionally inactive and functions as a strong ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity. Although the precise mechanism of hPRA-mediated transrepression is not fully understood, an inhibitory domain (ID) within human PR, which is necessary for transrepression by hPRA, has been identified. Interestingly, although ID is present within both hPR isoforms, it is functionally active only in the context of hPRA, suggesting that the two receptors adopt distinct conformations within the cell which allow hPRA to interact with a set of cofactors that are different from those recognized by hPRB. In support of this hypothesis, we identified, using phage display technology, hPRA-selective peptides which differentially modulate hPRA and hPRB transcriptional activity. Furthermore, using a combination of in vitro and in vivo methodologies, we demonstrate that the two receptors exhibit different cofactor interactions. Specifically, it was determined that hPRA has a higher affinity for the corepressor SMRT than hPRB and that this interaction is facilitated by ID. Interestingly, inhibition of SMRT activity, by either a dominant negative mutant (C'SMRT) or histone deacetylase inhibitors, reverses hPRA-mediated transrepression but does not convert hPRA to a transcriptional activator. Together, these data indicate that the ability of hPRA to transrepress steroid hormone receptor transcriptional activity and its inability to activate progesterone-responsive promoters occur by distinct mechanisms. To this effect, we observed that hPRA, unlike hPRB, was unable to efficiently recruit the transcriptional coactivators GRIP1 and SRC-1 upon agonist binding. Thus, although both receptors contain sequences within their ligand-binding domains known to be required for coactivator binding, the ability of PR to interact with cofactors in a productive manner is regulated by sequences contained within the amino terminus of the receptors. We propose, therefore, that hPRA is transcriptionally inactive due to its inability to efficiently recruit coactivators. Furthermore, our experiments indicate that hPRA interacts efficiently with the corepressor SMRT and that this activity permits it to function as a transdominant repressor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757795      PMCID: PMC85605          DOI: 10.1128/MCB.20.9.3102-3115.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II).

Authors:  N H Ing; J M Beekman; S Y Tsai; M J Tsai; B W O'Malley
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

2.  Control of c-Jun activity by interaction of a cell-specific inhibitor with regulatory domain delta: differences between v- and c-Jun.

Authors:  V R Baichwal; R Tjian
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms.

Authors:  M E Meyer; C Quirin-Stricker; T Lerouge; M T Bocquel; H Gronemeyer
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

Review 4.  Transcription activation by estrogen and progesterone receptors.

Authors:  H Gronemeyer
Journal:  Annu Rev Genet       Date:  1991       Impact factor: 16.830

5.  The cell-type-specific activator region of c-Jun juxtaposes constitutive and negatively regulated domains.

Authors:  V R Baichwal; A Park; R Tjian
Journal:  Genes Dev       Date:  1992-08       Impact factor: 11.361

6.  Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.

Authors:  L Nagy; H Y Kao; D Chakravarti; R J Lin; C A Hassig; D E Ayer; S L Schreiber; R M Evans
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

7.  Carboxy-terminal elements of c-Myb negatively regulate transcriptional activation in cis and in trans.

Authors:  J W Dubendorff; L J Whittaker; J T Eltman; J S Lipsick
Journal:  Genes Dev       Date:  1992-12       Impact factor: 11.361

8.  Identification of a negative regulatory function for steroid receptors.

Authors:  D P McDonnell; E Vegeto; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.

Authors:  E Vegeto; M M Shahbaz; D X Wen; M E Goldman; B W O'Malley; D P McDonnell
Journal:  Mol Endocrinol       Date:  1993-10

10.  Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast.

Authors:  T A Pham; Y P Hwung; D Santiso-Mere; D P McDonnell; B W O'Malley
Journal:  Mol Endocrinol       Date:  1992-07
View more
  85 in total

1.  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Authors:  Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

2.  Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor.

Authors:  Paloma H Giangrande; Timothy C Hallstrom; Chainarong Tunyaplin; Kathryn Calame; Joseph R Nevins
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 3.  Progesterone receptors in mammary gland development and tumorigenesis.

Authors:  Orla M Conneely; Biserka M Jericevic; John P Lydon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

Review 4.  Progesterone regulation of reproductive function through functionally distinct progesterone receptor isoforms.

Authors:  Orla M Conneely; Biserka M Jericevic
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

5.  Progesterone receptor-A and -B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition.

Authors:  Huiqing Tan; Lijuan Yi; Neal S Rote; William W Hurd; Sam Mesiano
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

6.  Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells.

Authors:  Xianfeng Fang; Xuxin Zhang; Meng Zhou; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

Review 7.  Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit.

Authors:  Hitoshi Ishimoto; Robert B Jaffe
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

Review 8.  Progesterone receptors, their isoforms and progesterone regulated transcription.

Authors:  Britta M Jacobsen; Kathryn B Horwitz
Journal:  Mol Cell Endocrinol       Date:  2011-09-17       Impact factor: 4.102

9.  In search of novel drug target sites on estrogen receptors using RNA aptamers.

Authors:  Daiying Xu; Vamsee-Krishna Chatakonda; Antonis Kourtidis; Douglas S Conklin; Hua Shi
Journal:  Nucleic Acid Ther       Date:  2014-03-03       Impact factor: 5.486

10.  Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro.

Authors:  Geetha V Rayasam; Cem Elbi; Dawn A Walker; Ronald Wolford; Terace M Fletcher; Dean P Edwards; Gordon L Hager
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.